As more people with type 2 diabetes (T2D) are taking medications to help manage blood sugar levels and weight loss, concerns about whether these drugs are safe have emerged. Now real-world evidence ...
Analysts have recently evaluated Exelixis and provided 12-month price targets. The average target is $29.4, accompanied by a high estimate of $33.00 and a low estimate of $27.00. This upward trend is ...